27,234 Shares in Masimo Corporation $MASI Acquired by Wilson Asset Management International PTY Ltd.

Key Points

• Wilson Asset Management International PTY Ltd. acquired 27,234 shares of Masimo Corporation, valued at approximately $4.58 million, making it the 28th largest position in their portfolio.
• Insider activity increased as Director William R. Jellison purchased 3,000 shares at an average cost of $145.98 each, raising his ownership of Masimo stock by 167.60%.
• Masimo's stock has a current market cap of $8.04 billion and analysts have a consensus rating of "Moderate Buy," with a price target averaging around $194.60.

Wilson Asset Management International PTY Ltd. bought a new position in shares of Masimo Corporation (NASDAQ:MASI - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 27,234 shares of the medical equipment provider's stock, valued at approximately $4,581,000. Masimo accounts for about 1.1% of Wilson Asset Management International PTY Ltd.'s investment portfolio, making the stock its 28th largest position. Wilson Asset Management International PTY Ltd. owned approximately 0.05% of Masimo at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. GAMMA Investing LLC grew its stake in Masimo by 58.4% in the first quarter. GAMMA Investing LLC now owns 738 shares of the medical equipment provider's stock valued at $123,000 after acquiring an additional 272 shares during the period. Strs Ohio acquired a new stake in Masimo in the first quarter valued at approximately $6,686,000. Swedbank AB acquired a new stake in Masimo in the first quarter valued at approximately $12,645,000. Harbor Capital Advisors Inc. acquired a new stake in Masimo in the second quarter valued at approximately $4,443,000. Finally, Intech Investment Management LLC grew its stake in Masimo by 26.8% in the first quarter. Intech Investment Management LLC now owns 32,494 shares of the medical equipment provider's stock valued at $5,414,000 after acquiring an additional 6,872 shares during the period. Institutional investors and hedge funds own 85.96% of the company's stock.

Insider Activity

In other news, Director William R. Jellison acquired 3,000 shares of the business's stock in a transaction dated Monday, August 11th. The stock was purchased at an average cost of $145.98 per share, for a total transaction of $437,940.00. Following the acquisition, the director owned 4,790 shares of the company's stock, valued at $699,244.20. This trade represents a 167.60% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 16.90% of the company's stock.

Masimo Price Performance

Masimo stock opened at $148.01 on Tuesday. Masimo Corporation has a 52 week low of $133.70 and a 52 week high of $194.88. The business has a 50-day simple moving average of $145.76 and a 200 day simple moving average of $155.04. The company has a quick ratio of 1.61, a current ratio of 2.14 and a debt-to-equity ratio of 0.57. The stock has a market cap of $8.04 billion, a price-to-earnings ratio of -17.37 and a beta of 1.28.

Masimo (NASDAQ:MASI - Get Free Report) last posted its earnings results on Thursday, June 20th. The medical equipment provider reported $1.42 EPS for the quarter. Masimo had a positive return on equity of 26.54% and a negative net margin of 24.85%.The business had revenue of $617.00 million during the quarter. On average, research analysts forecast that Masimo Corporation will post 4.1 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on MASI shares. BTIG Research restated a "buy" rating and issued a $198.00 target price on shares of Masimo in a report on Thursday, September 11th. Piper Sandler lifted their price target on Masimo from $200.00 to $210.00 and gave the stock an "overweight" rating in a report on Wednesday, August 6th. Wall Street Zen upgraded Masimo from a "hold" rating to a "buy" rating in a report on Tuesday. Weiss Ratings reiterated a "sell (d)" rating on shares of Masimo in a report on Wednesday, October 8th. Finally, Zacks Research upgraded Masimo from a "hold" rating to a "strong-buy" rating in a report on Wednesday, September 3rd. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $194.60.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.